Summit Therapeutics Inc (SMMT) concluded trading on Thursday at a closing price of $21.82, with 3.5 million shares of worth about $76.43 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 93.96% during that period and on February 13, 2025 the price saw a gain of about 11.50%. Currently the company’s common shares owned by public are about 737.09M shares, out of which, 114.59M shares are available for trading.
Stock saw a price change of 5.56% in past 5 days and over the past one month there was a price change of 31.05%. Year-to-date (YTD), SMMT shares are showing a performance of 22.28% which increased to 367.24% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.10 but also hit the highest price of $33.89 during that period. The average intraday trading volume for Summit Therapeutics Inc shares is 2.13 million. The stock is currently trading 2.23% above its 20-day simple moving average (SMA20), while that difference is up 12.33% for SMA50 and it goes to 45.96% higher than SMA200.
Summit Therapeutics Inc (NASDAQ: SMMT) currently have 737.09M outstanding shares and institutions hold larger chunk of about 12.04% of that.
The stock has a current market capitalization of $16.08B and its 3Y-monthly beta is at -1.06. It has posted earnings per share of -$0.28 in the same period. It has Quick Ratio of 8.31 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SMMT, volatility over the week remained 8.92% while standing at 7.55% over the month.
Stock’s fiscal year EPS is expected to rise by 70.17% while it is estimated to decrease by -38.79% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Truist on January 08, 2025 offering a Buy rating for the stock and assigned a target price of $35 to it. Coverage by Wells Fargo stated Summit Therapeutics Inc (SMMT) stock as an Overweight in their note to investors on December 11, 2024, suggesting a price target of $30 for the stock. On December 06, 2024, Jefferies Initiated their recommendations, while on November 04, 2024, JMP Securities Initiated their ratings for the stock with a price target of $32. Stock get a Neutral rating from Citigroup on September 27, 2024.
